The developer of the Russian vaccine assessed its effectiveness higher than the American one

Pakistan passes a decree that will allow to castrate and even hang those convicted of rape

The federal cabinet of the Government of Pakistan has approved on Wednesday two decrees to fight against increasing number of violations suffered by the...

Spain, Italy, Greece and Malta join forces to reject the EU migration pact

The four presidents send a letter to Merkel demanding that they not be left alone in this crisisOpen war against the migratory pact just...

In Mexico, ten women are murdered every day

On the International Day for the Elimination of Violence against Women, the UN warns of the additional damage that the pandemic has caused.Mexico reaches...

Tragedy in Brazil: at least 40 dead in a collision between a truck and a bus

The accident occurred in the interior of the state of San Pablo, near Taguaí. Workers from a textile company were traveling on the...

Coronavirus: Germany, the first European health power, runs out of doctors

Beds and respirators are surplus, but health personnel are lacking since before the pandemic. The virus made the crisis worse.Germany is the first...

According to the results of the interim assessment of the third phase of clinical trials of the Sputnik V vaccine, the effectiveness of the drug was 92%, the developers say. No serious adverse events were found in the vaccinated.

Center specialists. The Gamalei conducted the first interim analysis of the third phase of clinical trials and evaluated the effectiveness of the vaccine based on the results of observations of 16,000 volunteers 21 days after the second injection. The statistical analysis included 20 confirmed cases identified in the vaccine and placebo groups. Experts estimated the effectiveness of the Sputnik V vaccine at 92%, reports Russian Direct Investment Fund (RDIF).

An assessment was also made of observations of 10,000 medical personnel who received the vaccine outside of clinical trials. In this group, the effectiveness of the drug was 90%. None of the groups showed any unexpected side effects. Some of the vaccinated had pain at the injection site, fever, weakness, but all these conditions were short-term. The RDIF report indicates that the team of the Gamaleya Center plans to publish the obtained data in one of the leading peer-reviewed medical publications.

On November 9, the American pharmaceutical company Pfizer and its German biotechnological partner BioNTech announced similar results of the III phase of clinical trials of a vaccine against coronavirus. The short report states that the BNT162b2 coronavirus drug has shown an efficacy of more than 90% in clinical trials involving volunteers. Pfizer intends to ask the Food and Drug Administration (FDA) to authorize the vaccine for emergency use.

Earlier, the World Health Organization said that it would consider the COVID-19 vaccine effective only if it works 50% of the time for several months.



Related Articles